T he role of Ca 2ϩ signaling in the activation of T lymphocytes is well established (1, 2). Binding of the TCR to Ag associated with the MHC initiates a cascade of intracellular signaling that culminates in the production of cytokines and T cell proliferation. Among the proximal signaling steps that take place at the plasma membrane, tyrosine phosphorylation of substrates, including phospholipase C, generates two key second messengers, diacylglycerol, leading to the activation of protein kinase C, and 1,4,5-inositol trisphosphate (IP 3 ), 5 leading to the initiation of the Ca 2ϩ signal. The Ca 2ϩ signal is sustained by the activation of a specific type of store-operated Ca 2ϩ channel in the plasma membrane called the Ca 2ϩ release-activated Ca 2ϩ (CRAC) channel (1). Ca 2ϩ signaling must be oscillatory or sustained at the level of individual cells to activate gene transcription via the NF-AT pathway, leading to cytokine production (3-5).
T he role of Ca 2ϩ signaling in the activation of T lymphocytes is well established (1, 2) . Binding of the TCR to Ag associated with the MHC initiates a cascade of intracellular signaling that culminates in the production of cytokines and T cell proliferation. Among the proximal signaling steps that take place at the plasma membrane, tyrosine phosphorylation of substrates, including phospholipase C, generates two key second messengers, diacylglycerol, leading to the activation of protein kinase C, and 1,4,5-inositol trisphosphate (IP 3 ), 5 leading to the initiation of the Ca 2ϩ signal. The Ca 2ϩ signal is sustained by the activation of a specific type of store-operated Ca 2ϩ channel in the plasma membrane called the Ca 2ϩ release-activated Ca 2ϩ (CRAC) channel (1) . Ca 2ϩ signaling must be oscillatory or sustained at the level of individual cells to activate gene transcription via the NF-AT pathway, leading to cytokine production (3) (4) (5) .
The level of cellular tyrosine phosphorylation and subsequent activation events are controlled by a balance between phosphorylation and dephosphorylation reactions. Thus, compounds that alter the balance of kinase and phosphatase activity may profoundly influence cellular activation in the immune response. Sodium orthovanadate (Na 3 VO 4 ) is a potent inhibitor of protein tyrosine phosphatase (PTPs) and other phosphoryl transfer enzymes (6) . In the ϩ5 oxidation state, vanadate adopts a trigonal bipyramidal configuration that mimics the phosphate ion (7) . In this configuration, Na 3 VO 4 competes with the ␥-phosphate of ATP for binding to the active site of the Na ϩ ,K ϩ -ATPase, thus inhibiting the enzyme (8, 9) . Na 3 VO 4 inhibits PTPs by a similar mechanism (reviewed in Refs. 10 -12) . Formation of a phosphate-thioester bond with a conserved cysteine at the active site of PTPs is critical to the dephosphorylation reaction. Na 3 VO 4 reversibly displaces phosphate from the active site thiol (13) . In addition, thiol oxidation may permanently inactivate PTPs during prolonged treatment of cells with Na 3 VO 4 (14) . Cysteine could be oxidized directly by Na 3 VO 4 or indirectly following the intracellular formation of pervanadate. Pervandate is a complex mixture of peroxovanadium compounds formed in vitro by mixing H 2 O 2 and Na 3 VO 4 (reviewed in Ref. 10) . Pervanadate produces an irreversible inhibition of PTPs that can be prevented by preincubation with thiol-reducing agents, suggesting that the effect of pervanadate is mediated by the oxidation of cysteine (15) . Although vanadate and pervanadate have been widely used as general inhibitors of PTPs and clearly enhance tyrosine phosphorylation in immune cells (16 -20) , the effects of vanadium compounds on other cellular targets as a result of their thiol reactivity have not been fully explored.
The modulation of intracellular signaling by vanadium compounds takes on a greater significance because they are being considered as potential therapeutic agents for use in both insulin-dependent and noninsulin-dependent forms of diabetes (21) (22) (23) (24) (25) . Their insulin-mimetic actions in vivo and in vitro correlate with their ability to inhibit PTPs and induce phosphorylation of the ␤ subunit of the insulin receptor (26 -30) . Recent studies have shown that concentrations of vanadium compounds that increase glucose transport and normalize blood glucose levels (21, 31, 32) also produce tyrosine phosphorylation and Ca 2ϩ mobilization in Jurkat T cells (16, 17, 33) and RBL cells (18) . Thus, potential actions by these compounds on the immune system must also be considered.
Previous attempts to characterize the action of vanadate on cells of the immune system have yielded conflicting results. In Jurkat T cells, pervanadate was reported to induce Ca 2ϩ influx independent of store release (17) . However, in RBL cells pervanadate appeared to release Ca 2ϩ from intracellular stores (18) . In many cell types, Ca 2ϩ influx is coupled to the depletion of intracellular Ca 2ϩ stores by a process termed capacitative Ca 2ϩ entry (34, 35) . In lymphocytes and RBL cells store release leads to CRAC channel activation (36 -42 
Materials and Methods

Cell culture
The human leukemia T cell line, Jurkat E6-1, and the rat basophilic leukemia cell line, RBL-2H3, were obtained from American Type Culture Collection (Manassas, VA). Jurkat-NZ cells containing a ␤-galactosidase reporter gene construct (lacZ) under the control of the NF-AT promoter were derived from the Jurkat subline NZDipA.1.5.22 and have been previously described and characterized (4) . Jurkat E6-1 and Jurkat-NZ cells were grown in RPMI 1640 medium containing 10% heat-inactivated FBS, 10 mM HEPES, and 2 mM glutamine. Cells were cultured in 25-ml flasks (Costar, Cambridge, MA) at 37°C in 5% CO 2 in a humidified incubator. RBL cells were maintained in Eagle's MEM supplemented with 20% FCS and 2 mM glutamine. RBL cells were plated onto glass coverslips 1-2 days before use.
Chemicals
Thapsigargin (TG) and dipotassium oxodiperoxo (pyridine-2-carboxylato) vanadate (bpV(pic)) were obtained from Alexis Biochemicals (San Diego, CA). 5Ј-Adenlylimidodiphosphate tetralithium salt was obtained from Roche Molecular Biochemicals (Basel, Switzerland), and adenosine 5Ј-o-(3-thiotriphosphate) tetralithium salt (ATP␥S) was obtained from Calbiochem (San Diego, CA). All other salts and reagents were obtained from Sigma-Aldrich (St. Louis, MO).
Calcium imaging
Jurkat T cells were loaded with 3 M fura-2-AM (Molecular Probes, Eugene, OR) for 30 -40 min at room temperature (20 -25°C). The cells were then washed three times with RPMI/10% FCS. RBL cells were loaded in medium containing 1 M fura-2-AM and 2.5 mM probenecid for 30 min at 37°C in the incubator. These cells were then washed three times with Eagle's MEM containing 2.5 mM probenecid and returned to the incubator for an additional 30 min to complete the hydrolysis of the fura-2 ester. After fura-2 loading, all cells were stored at room temperature in the dark until use. Before imaging, media were exchanged with mammalian Ringer containing: 160 mM NaCl, 4.5 mM KCl, 2 mM CaCl 2 , 1 mM MgCl 2 , 10 mM glucose, and 10 mM HEPES (pH 7.4; osmolality, 290 -310 mOsm/ kg). Illumination was provided by a xenon arc lamp (Carl Zeiss, New York, NY) and transmitted through a filter wheel unit (Lambda 10, Axon Instruments, Foster City, CA) containing 350-and 385-nm excitation filters. The filtered light was reflected by a 400-nm dichroic mirror through a ϫ63 oil immersion objective to illuminate cells. Emitted light above 480 nm was received by an intensified CCD camera (C2400, Hamamatsu Photonics, Bridgewater, NJ), and the video information was relayed to an image processing system (Videoprobe, ETM Systems, Petaluma, CA). Full field-ofview 8-bit images, averaged over 16 frames, were collected at 350-and 385-nm wavelengths. Digitally stored 350/385 ratios were constructed from background-corrected 350-and 385-nm images. Single-cell measurements of [Ca 2ϩ ] i were calculated from the 350/385 ratios using the equation of Grynkiewicz et al. (43) 
Microinjection
The sodium salt of low molecular mass heparin (average m.w., 3 kDa; Sigma, St. Louis, MO) was made up to a concentration of 25 mg/ml in a 100 mM KCl solution containing 0.1% tetramethylrhodamine dextran (Molecular Probes). The heparin solution was loaded into prepulled glass capillaries (Femtotip, Eppendorf, Hamburg, Germany). Cell microinjection was performed using a pressure injector (model 5246, Eppendorf) and micromanipulator (model 5171, Eppendorf) as previously described (44) . Microinjections were performed 2 h before the calcium imaging experiments.
Whole-cell recording
Membrane currents were measured in Jurkat T cells using the whole-cell configuration of the patch-clamp technique (45, 46) . An EPC-9 amplifier (HEKA, Lambrecht, Germany) interfaced to a Macintosh Quadra 700 computer (Apple Computer, Cupertino, CA) was used for pulse application and data recording. Membrane voltages were corrected for liquid junction potentials, and current recordings were corrected for leak and capacitative currents. Patch pipettes were pulled from Accu-fill 90 Micropets (Becton Dickinson, Parsippany, NJ) using a P87 micropipette puller (Sutter Instruments, Novato, CA). Pipettes were coated with Sylgard (Dow Corning, Midland, MI) and heat polished to a final resistances of 2-5 M⍀. Patchclamp experiments were performed at room temperature (20 -25°C). Unless otherwise indicated the membrane currents were filtered at 1.5 kHz. Data analysis was performed using the program Pulse (HEKA, Lambrecht, Germany). During the whole-cell recordings, the membrane potential was held at 0 mV, and the Ca 2ϩ current through CRAC channels was measured during 200-ms voltage ramps from Ϫ100 to ϩ40 mV applied at 1-s intervals. The pipette solution contained 128 mM Cs ϩ aspartate, 12 mM bis(2-aminophenoxy)ethane-N,N,NЈ,NЈ-tetraacetate (BAPTA), 0.9 mM CaCl 2 , 3.16 mM MgCl 2 , and 10 mM HEPES; was titrated to pH 7.2 with CsOH; and had an estimated free Ca 2ϩ concentration of 10 nM. The external solution had the following composition: 150 mM NaMeSO 3 , 20 mM CaCl 2 , 10 mM glucose, and 10 mM HEPES and was titrated to pH 7.4 with NaOH.
The lacZ reporter gene assay
The expression of lacZ was measured using a fluorescence assay as previously described (47) . In brief, Jurkat-NZ cells were seeded at 1 ϫ 10 5 cells/well in 96-well plates containing culture medium alone or with addition of 1 M TG or varying concentrations of bpV(pic), each condition in the presence or the absence of 50 nM PMA. The cells were activated in a humidified incubator at 37°C with 5% CO 2 for 10 h, then lysed and incubated with 3 mM 4-methylumbelliferyl ␤-D-galactopyranoside (Molecular Probes). The fluorescence signal measured in a multiwell plate reader (CytoFluor Series 4000, Perspective Biosystems, Framingham, MA; 400 nm excitation, 505 nm emission) is proportional to lacZ activity driven by the NF-AT pathway.
Data analysis
Numerical values for single-cell [Ca 2ϩ ] i traces were analyzed with Origin (Microcal, Northhampton, MA). Statistical analysis was performed on data sets using Excel v5.0 (Microsoft, Redmond, WA). Data are reported as the mean Ϯ SD. Multisample hypotheses were tested using a single-factor ANOVA and performing a Dunnett's test to determine the significance of differences from control values. Data were considered statistically different at p Ͻ 0.05.
Results
The bpV(pic) activates Ca 2ϩ signaling in Jurkat T lymphocytes and RBL-2H3 mast cells
Previous studies (17, 18) demonstrated that application of peroxovanadium compounds increased [Ca 2ϩ ] i in both RBL cells and Jurkat T cells. However, different mechanisms have been postulated for the Ca 2ϩ increase in each cell type. These differences may have been due to cell-specific effects of pervanadate or to different mixtures of peroxyvanadium compounds being used each study. To test the hypothesis that peroxyvanadium compounds act by a similar mechanism on T cells and mast cells we tested the effects of the cell-permeant peroxyvanadium compound, bpV(pic) on Jurkat T cells and RBL mast cells. When exposed to bpV(pic) (200 M) in the presence of extracellular Ca 2ϩ , most Jurkat T cells (80 Ϯ 10%) responded after a variable delay with an abrupt increase in [Ca 2ϩ ] i . In the majority of responding cells the initial rise in [Ca 2ϩ ] i was followed by slow oscillations with a 73 Ϯ 4-s period and a peak [Ca 2ϩ ] i near 700 nM (Fig. 1A) . The average Ca 2ϩ response from all observed cells (Fig. 1A , bottom graph) rose smoothly from the resting level of 66 Ϯ 41 nM to a plateau of 488 Ϯ 210 nM. This population response reflects the asynchronous Ca 2ϩ oscillations in single cells and the fact that the average includes nonresponding cells. Our data confirm earlier observations that peroxovanadium compounds increase [Ca 2ϩ ] i in Jurkat T cells (16, 17) and reveal at the single-cell level that bpV(pic) can produce Ca 2ϩ oscillations analogous to those produced during Ag presentation (48) . Extracellular Ca 2ϩ is required to maintain the bpV(pic)-induced oscillations, because exchanging the bath solution with nominally Ca 2ϩ -free Ringer's solution rapidly and reversibly terminated the oscillations (Fig. 1A, application bar) .
Treatment of RBL cells with pervanadate results in Ca 2ϩ responses that vary with the peroxovanadium compounds formed in the mixture (18) . Using bpV(pic), we characterized the effects of a single form of peroxovanadate on RBL cells. The average response of RBL cells to 200 M bpV(pic) closely resembled that of the Jurkat T cells (Fig. 1B) (Fig. 2) . In the averaged response (Fig. 2,  bottom 
The NF-AT-driven gene expression is induced by bpV(pic)
To assess the long term effects of vanadate treatment, we monitored transcriptional activation of the Ca 2ϩ -sensitive transcription factor, NF-AT. Jurkat-NZ cells contain a reporter construct in which the ␤-galactosidase gene (lacZ) is driven by a triple, tandem repeat of the NF-AT binding element found in the T cell IL-2 promoter. When Jurkat-NZ cells are activated, the translocation of NF-AT to the nucleus causes a dramatic increase in ␤-galactosidase production that can be assessed by fluorogenic substrates (4).
Stimulation of Jurkat-NZ cells with PMA and TG caused a large increase in NF-AT activity, whereas PMA or TG alone had little effect (Fig. 3) . Parallel experiments with bpV(pic) yielded a smaller, but still significant, increase in NF-AT activity over that in untreated cells regardless of the presence of PMA (Fig. 3) . The ability of vanadate to induce NF-AT activity in the absence of PMA contrasts with the PMA requirement for gene expression triggered by TG or ionomycin (4, 50) . These results suggest that vanadate may also act to induce PKC activity. ] i and several oscillations before [Ca 2ϩ ] i returns to baseline levels. As expected, heparin-injected RBL cells (Fig. 4B) did not respond to purinergic stimulation. Stimulation by bpV(pic) was inhibited by heparin injection (Fig.  5) . Both the initial Ca 2ϩ transient and the delayed Ca 2ϩ plateau were completely blocked. In contrast, heparin preinjection did not inhibit Ca 2ϩ responses evoked by TG or ionomycin (data not shown), demonstrating that heparin did not interfere directly with CRAC channel function. Microinjection with control dextrans had no effect on the Ca 2ϩ response to bpV(pic). We conclude that both transient and sustained bpV(pic)-mediated Ca 2ϩ signals require IP 3 -dependent release of Ca 2ϩ .
Vanadate, bpV(pic), and IP 3 enhance the rate of activation of CRAC channels
In Jurkat T cells, depletion of intracellular Ca 2ϩ stores results in the opening of CRAC channels and Ca 2ϩ influx. During passive store depletion by intracellular dialysis with heavily buffered low Ca 2ϩ solutions, an initial lag period was followed by the development of inward Ca 2ϩ current through CRAC channels (Fig. 6 ). These currents exhibit inward rectification, voltage-independent gating, and a reversal potential beyond ϩ40 mV. Inclusion of bpV(pic) in the pipette solution accelerated the activation of the CRAC currents without altering their rectification or reversal potential (Fig. 6) . Using the amplitude of the current at Ϫ80 mV, we compared the effects of bpV(pic) and vanadate with that of IP 3 on the activation of CRAC currents (Fig. 7) . When the channels were activated by passive store depletion alone, the current reached its maximum (Ϫ1.18 Ϯ 0.6 pA/pF) within 260 s (t 1/2 ϭ 122 Ϯ 48 s; Fig. 7A and Table I ). Addition of IP 3 (10 M) to the intracellular currents through CRAC channels were made during passive store depletion alone (A) or during intracellular dialysis with 10 M bpV(pic) (B). Voltage clamp protocol: 200-ms ramps from Ϫ120 to ϩ40 mV were taken from a holding potential of 0 mV at intervals of 1 s. Currents during ramps taken before CRAC current induction and after maximal activation are shown. Currents from the first five ramps obtained after beginning whole-cell recording were averaged, and the average was subtracted from the remaining records to eliminate leak currents. The time after establishing the whole-cell patch clamp configuration is indicated to the left of each current-voltage plot.
FIGURE 7.
Time course of CRAC current activation. Whole-cell recordings of Ca 2ϩ currents through CRAC channels were made in Jurkat T cells during passive store depletion (A) or during intracellular dialysis with 10 M IP 3 (B), 10 M Na 3 VO 4 (C ), or 10 M bpV(pic) (D). Currents were recorded as described in Fig. 6 , and the CRAC current density at Ϫ80 mV is shown from time that the whole-cell patch clamp configuration was established (t ϭ 0). solution accelerated activation of the CRAC current, reducing the t 1/2 of activation to 14 Ϯ 7 s, but did not alter the final amplitude of the current (Fig. 7B and Table I ). Dialysis of the cell with solutions containing bpV(pic) or Na 3 VO 4 (10 M) also accelerated the activation of CRAC channels (Fig. 7, C and D) reducing the t 1/2 to 14 Ϯ 5 and 29 Ϯ 18 s, respectively. Thus, the enhanced rate of activation of CRAC currents by Na 3 VO 4 and bpV(pic) mimicked the well-studied effects of IP 3 on CRAC currents.
The effect of Na 3 VO 4 on the rate of CRAC channel activation does not require ATP
The actions of Na 3 VO 4 and bpV(pic) on CRAC channels could result from increased tyrosine phosphorylation secondary to phosphatase inhibition. We used nucleotide replacement to test whether the effects of NaVO 4 could be duplicated by changes in the level of cellular phosphorylation. ATP␥S is an ATP analogue that is readily used by kinases (53) (54) (55) (56) . When the thiophosphoryl group from ATP␥S is transferred to a protein, the resulting bond is resistant to the action of phosphatases. Therefore, nucleotide substitution of ATP␥S for ATP should mimic the effects of inhibiting intracellular phosphatases. Intracellular dialysis with 5 mM ATP␥S did not alter the amplitude or rate of activation of CRAC currents (Table I) . Furthermore, intracellular dialysis with adenlylimidodiphosphate tetralithium salt (5 mM), a nonhydrolyzable analogue of ATP that should reduce protein phosphorylation, did not reduce the rate of CRAC channel activation. In addition, the serine phosphatase inhibitors okadaic acid and calyculin did not increase the rate of CRAC channel activation (Table I) . Thus, treatments that shift the phosphorylation status of cellular proteins did not duplicate the effects of vanadate on CRAC channels.
Thiol oxidation mediates the effects of vanadate on CRAC current activation
To determine whether the effects of vanadate on CRAC currents are mediated by interaction with cysteine residues, we tested whether the action of Na 3 VO 4 could be prevented by the thiolreducing agent DTT. Fig. 8 , A-C, shows that DTT (5 mM; in pipette and bath) prevented the activation of CRAC currents by Na 3 VO 4 (10 M). Comparison of rates of activation shows that DTT can prevent activation of CRAC currents by Na 3 VO 4 , but not IP 3 (Table I ). To test whether thiol oxidation alone could enhance the activation of CRAC channels, we included chloramine T, an agent that selectively oxidizes methionine and cysteine residues (57), in the intracellular solution. The rate of activation of CRAC channels was enhanced by chloramine T with respect to activation during passive store depletion (Fig. 8, C and D, and Table I ). These data demonstrate that intracellular dialysis with vanadate or chloramine T produces an increased rate of activation of CRAC currents. Shifting the intracellular redox state to a more reducing environment eliminates the activity of both compounds, suggesting that the effects of vanadate and chloramine T are mediated by thiol oxidation. We further evaluated the hypothesis that chloramine T and vanadate act via the same mechanism. Fig. 9A shows that chloramine T, like pbV(pic) (Fig. 5) , produces a gradual rise in [Ca 2ϩ ] i from baseline to micromolar levels that was inhibited by preinjection with heparin. Thus, Ca 2ϩ signaling induced by either . Currents were recorded as described in Fig. 6 and are shown from time that the whole-cell patch clamp configuration was established (t ϭ 0). 
Discussion
The data presented above demonstrate that treatment with the peroxovanadium compound, bpV(pic), (Fig.  2) . Furthermore, heparin inhibited vanadate-induced Ca 2ϩ entry in RBL cells (Fig. 5) , indicating that Ca 2ϩ entry is secondary to intracellular Ca 2ϩ store depletion and requires the binding of IP 3 to its receptor in the endoplasmic reticulum. Finally, currents activated by vanadate were indistinguishable in every characteristic from those activated by dialysis with IP 3 or by passive Ca 2ϩ store depletion (Fig. 6) . Taken together, our results eliminate the possibility that vanadate produces Ca 2ϩ influx by direct activation of CRAC channels or any other Ca 2ϩ influx mechanism. These data are consistent with earlier studies showing pervanadate-induced Ca 2ϩ entry secondary to store release in single RBL cells (18) , but conflict with results in Jurkat T cells suggesting that pervanadate directly activates membrane Ca 2ϩ channels (17) . The latter conclusion was drawn when a rise in [Ca 2ϩ ] i was not observed in the absence of extracellular Ca 2ϩ . However, that study was performed on cell suspensions using a spectrophotometer in which the average Ca 2ϩ response from many cells was sampled simultaneously. Our results using video imaging of individual cells show that Ca 2ϩ transients occur asynchronously following treatment with bpV(pic). Small transients in the absence of extracellular Ca 2ϩ would be missed in population studies (see, for example, Fig. 2B ). Therefore, we conclude that vanadate induces Ca 2ϩ influx secondarily to promoting IP 3 production and Ca 2ϩ store release, consistent with previous results demonstrating increased PLC␥ activity and higher cytosolic IP 3 levels in intact cells (16, 18) .
How does vanadate act chemically inside the cell to promote Ca 2ϩ signaling? Vanadate and bpV(pic) are multifunctional reagents that can interact with a number of cellular components in two primary modes of action: 1) mimicking the transition state complex formed by the phosphate ion during phosphoryl transfer reactions; and 2) directly oxidizing cysteine thiols (6) . Although Na 3 VO 4 does not shift the total cellular redox state in lymphocytes, which would appear to emphasize the importance of the first mechanism (19) , measurements of the total cellular redox state principally assess the status of nonprotein thiols; thus, the selective oxidation of active site cysteines may not be reflected in those experiments. In fact, a number of studies demonstrate that thiol oxidation plays an important role in the mechanism by which vanadium compounds inhibit PTPs. First, inactivation of PTP1B by vanadium compounds is prevented, but not reversed, by the reducing agent DTT (15) . Second, pervanadate directly oxidizes the active site cysteine to cysteic acid in PTP1B (15) . Third, Na 3 VO 4 and pervanadate oxidize cysteine sulfhydryls (58) . Other agents that cause thiol oxidation, such as thimerosal, have been reported to enhance Ca 2ϩ release from intracellular stores through direct interaction with the IP 3 R (59 -61). Thimerosal was shown to increase both the single-channel conductance and the mean open time of the reconstituted Ca 2ϩ release channel (62) . In addition, thimerosal-induced Ca 2ϩ influx has been linked to the release of Ca 2ϩ from intracellular stores and the activation of CRAC channels in the plasma membrane of RBL-2H3 cells (63) . Our data show that chloramine T mimics and DTT reverses the activation of CRAC channels by Na 3 VO 4 and bpV(pic) (Figs. 8 and 9) . Thus, our results favor oxidation as vanadate's mode of action. The primary target must be more proximal than the IP 3 receptor, because heparin blocks bpV(pic)-induced Ca 2ϩ signaling. Furthermore, vanadate-induced gene expression did not require the presence of phorbol ester (Fig. 3) , suggesting a direct action of vanadate on PLC␥ to generate adequate diacylglycerol for PKC stimulation. Additional effects that might potentiate activity of the IP 3 R activity are not excluded.
Of the myriad of cellular actions demonstrated with vanadium compounds, their insulin-mimetic effects have garnered the most clinical interest. Micromolar concentrations of vanadate and peroxovanadium compounds stimulate hexose uptake, glucose oxidation, and lipogenesis in vivo and in vitro (26 -28, 31, 64) . Clinical trials demonstrating that sodium metavanadate and vanadyl sulfate improve insulin sensitivity and fasting blood glucose levels have led to suggestions for use of these agents in adjunctive therapy in diabetes (22) (23) (24) (25) . The clinically applied forms of vanadate have been shown to interconvert within the cell to the ϩ5 oxidation state and to pervandate depending upon the intracellular redox state (reviewed in Refs. 10, 11, and 65). Thus, the effects of vanadate on Ca 2ϩ signaling may contribute to the insulin-mimetic properties of these compounds. Unfortunately, beyond their beneficial metabolic effects, long term mitogenic and potentially tumorigenic effects of vanadium compounds must be considered (reviewed in Ref. 60 ). When applied to lymphocytes at clinically relevant concentrations, vanadium compounds mimic receptormediated activation. Our data show that bpV(pic) activates NF-AT-dependent gene expression in Jurkat T cells. Previous reports have demonstrated that peroxyvanadate compounds activate c-Jun and c-Fos and induce nuclear translocation of NF-B in lymphocytes (17, 19) . Recently, peroxovanadium compounds were shown to stimulate HIV-1 production in latently infected cell lines in conjunction with T cell activation (20) . Thus, studies of the mechanisms by which vanadium compounds interact with lymphocytes may have relevance to its proposed clinical application and yield new approaches to other diseases of the immune system.
